On CNBC’s "Mad Money Lightning Round," Jim Cramer said Illumina, Inc. ILMN is not even as good as Danaher Corporation DHR. "Be careful, that’s too much Illumina," he added.
When asked about COMPASS Pathways plc CMPS, he said, "Treatment resistant depression is incredibly difficult, no one’s really had a handle on it. Johnson & Johnson JNJ does have a good drug for it right now, but it’s just very, very difficult."
KeyCorp KEY reported a disappointing quarterly number. "Ok, so the stock got hammered immediately, and then bingo! It reverses and goes up. It is time to buy the stock of KeyCorp, which is an excellent company," he added.
Cramer said ASML Holding N.V. ASML reported a good quarter, but it didn’t matter as Taiwan Semi, the largest capital equipment buyer in the country, said that they don’t need as much capital equipment. "I think you got to wait three days before ASML is going to bottom, probably get it around six hundred," he added.
Don’t forget to check out our premarket coverage here
The "Mad Money" host, heard from a caller who stated that Verve Therapeutics, Inc. VERV is developing a drug that will reduce LDL cholesterol in one dose. Cramer responded, saying, the company is "trying to do that, and that would be remarkable if it does it, because many people are taking some very difficult drugs to reduce cholesterol. Some of us are allergic to them, and it would really be unbelievable if we could find something like this. So it would be fabulous, but it’s very speculative."
Cramer said he liked Informatica Inc. INFA before it went private, and he likes it now. "But the problem is now there are too many companies who do exactly what Informatica does, although they do it really well, and that’s what’s causing the problem, that’s what keeps me from saying buy, buy, buy," he added.
When asked about Eaton Corporation plc ETN, he said, "That new change in management has done incredibly well. It is really the linchpin of the entire change going towards electric vehicles."
Price Action: Shares of Eaton rose 0.5% to close at $210.91, while Informatica fell 1.6% to $18.69 on Thursday. Verve Therapeutics shares fell 2.6% to settle at $19.83, while ASML lost 5.5% to $676.13 during the Thursday’s session. KeyCorp shares gained 4.1% to close at $11.88, while COMPASS Pathways fell 1.4% to $8.96. Shares of Illumina declined 0.2% to settle at $184.17 on Thursday.
Now Read This: American Express, SLB And 3 Stocks To Watch Heading Into Friday
Photo: Shutterstock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.